Eli Lilly has agreed to acquire Prevail Therapeutics, a gene therapy company focused on the development of disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Prevail’s lead candidate, PR001, is a potentially disease-modifying single-dose AAV9-based gene therapy in development for Parkinson’s disease with GBA1 mutations and neuronopathic Gaucher disease. The deal, which values Prevail at US$1.04 B, comes one month after Lilly pledged up to US$2.7 B to partner with Precision BioSciences to develop in vivo therapies for genetic disorders.